Peru
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.51 (1.18 - 1.90) | 2015 | Modelled | WHO |
0.3 (0.30 - 0.40) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
0.4 (0.21 - 0.55) | 2015 | Survey/reported | Cabezas, C., et al. 2020 |
2.1 (1.90 - 2.32) | 2013 | Modelled | Schweitzer et al, 2015 |
0.5 (0.46 - 0.55) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.57 (0.52 - 0.64) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.53 - 0.65) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.53 - 0.64) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.53 - 0.64) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.59 (0.53 - 0.64) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.59 (0.54 - 0.65) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.54 - 0.65) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.55 - 0.66) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.55 - 0.67) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.55 - 0.67) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.55 - 0.68) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.69) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.69) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.55 - 0.70) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.70) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.55 - 0.69) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.69) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.69) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.55 - 0.69) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.55 - 0.69) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.68) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.69) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.56 - 0.69) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.55 - 0.70) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.55 - 0.69) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.55 - 0.69) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.54 - 0.68) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.54 - 0.68) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.54 - 0.67) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.56 (0.51 - 0.62) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.24 (0.16 - 0.35) | 2015 | Modelled | WHO |
0.04 (0.03 - 0.05) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.06 (0.04 - 0.07) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.07) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.08) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.07) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.07) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.08) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.08) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.05 - 0.08) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.07 (0.05 - 0.09) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.08 (0.06 - 0.11) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.1 (0.07 - 0.13) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.11 (0.08 - 0.15) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.12 (0.09 - 0.16) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.09 - 0.17) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.10 - 0.18) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.14 (0.10 - 0.18) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.14 (0.10 - 0.19) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.11 - 0.20) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.16 (0.12 - 0.21) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.18 (0.13 - 0.23) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.2 (0.15 - 0.26) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.22 (0.16 - 0.28) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.23 (0.17 - 0.29) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.23 (0.17 - 0.29) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.23 (0.17 - 0.29) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.23 (0.17 - 0.29) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.23 (0.17 - 0.29) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.22 (0.16 - 0.29) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.05 - 0.07) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
92,000 (81,000 - 127,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
169,711 (155,721 - 188,009) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
180,112 (165,857 - 199,214) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
183,598 (168,372 - 203,974) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
183,893 (166,092 - 205,297) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
181,005 (164,779 - 199,189) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
178,463 (161,682 - 195,791) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
176,064 (159,899 - 192,839) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
173,504 (157,944 - 188,985) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
170,846 (155,367 - 185,999) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
168,711 (153,251 - 184,369) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
166,576 (150,323 - 182,821) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
164,893 (149,400 - 181,297) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
164,021 (148,130 - 181,280) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
163,365 (147,553 - 181,578) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
162,386 (145,780 - 182,100) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
160,659 (143,138 - 181,564) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
158,505 (142,115 - 178,738) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
156,487 (140,543 - 175,225) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
154,491 (139,110 - 172,267) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
152,395 (137,537 - 169,338) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
150,087 (135,089 - 167,133) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
147,950 (133,436 - 164,284) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
146,239 (131,867 - 162,549) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
144,613 (130,330 - 160,992) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
142,731 (127,959 - 160,002) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
140,290 (125,064 - 157,597) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
137,457 (122,764 - 153,993) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
134,582 (119,985 - 150,197) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
131,639 (116,884 - 146,738) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
128,606 (114,007 - 142,914) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
125,460 (110,788 - 139,755) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
2.49 (1.71 - 3.49) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
3.75 (3.04 - 4.68) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.6 (2.91 - 4.46) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.96 (3.26 - 4.84) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.03 (3.30 - 4.98) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.84 (3.09 - 4.73) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.12 (3.35 - 5.14) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
4.11 (3.41 - 5.04) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.96 (3.24 - 4.90) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.4 (2.67 - 4.24) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.84 (3.08 - 4.82) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.41 (2.67 - 4.37) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.21 (2.50 - 4.07) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.25 (2.56 - 4.06) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.23 (2.50 - 4.08) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.17 (2.41 - 4.09) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.14 (2.41 - 3.99) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.05 (2.33 - 3.92) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.89 (2.20 - 3.76) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.79 (2.13 - 3.60) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.93 (2.24 - 3.83) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.93 (2.20 - 3.86) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.88 (2.18 - 3.76) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.82 (2.18 - 3.64) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.75 (2.14 - 3.60) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.67 (2.05 - 3.46) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.63 (1.96 - 3.50) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.6 (1.88 - 3.57) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.56 (1.80 - 3.61) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.53 (1.74 - 3.58) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.49 (1.71 - 3.49) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
4,340 | 2016 | Modelled | WHO |
815 (660 - 1,017) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
796 (644 - 987) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
939 (769 - 1,161) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
908 (747 - 1,109) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
865 (697 - 1,066) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
976 (794 - 1,216) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
987 (821 - 1,213) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
968 (790 - 1,196) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
952 (762 - 1,195) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
867 (680 - 1,081) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
858 (672 - 1,099) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
841 (661 - 1,049) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
842 (655 - 1,066) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
857 (664 - 1,084) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
852 (648 - 1,099) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
804 (612 - 1,048) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
854 (657 - 1,084) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
840 (643 - 1,078) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
787 (599 - 1,015) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
837 (639 - 1,092) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
846 (641 - 1,104) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
846 (636 - 1,116) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
847 (657 - 1,108) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
846 (653 - 1,092) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
843 (630 - 1,125) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
841 (648 - 1,092) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
848 (612 - 1,166) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
852 (597 - 1,199) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
852 (585 - 1,206) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
846 (581 - 1,186) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
846 (581 - 1,186) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of HepB birth dose
Newborns
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
82 | 2019 | Survey/reported | WHO/UNICEF |
73 | 2018 | Survey/reported | WHO/UNICEF |
75 | 2017 | Survey/reported | WHO/UNICEF |
79 | 2016 | Survey/reported | WHO/UNICEF |
79 | 2015 | Survey/reported | WHO/UNICEF |
78 | 2014 | Survey/reported | WHO/UNICEF |
82 | 2013 | Survey/reported | WHO/UNICEF |
81 | 2012 | Survey/reported | WHO/UNICEF |
76 | 2011 | Survey/reported | WHO/UNICEF |
74 | 2010 | Survey/reported | WHO/UNICEF |
71 | 2009 | Survey/reported | WHO/UNICEF |
79 | 2008 | Survey/reported | WHO/UNICEF |
73 | 2007 | Survey/reported | WHO/UNICEF |
66 | 2006 | Survey/reported | WHO/UNICEF |
67 | 2005 | Survey/reported | WHO/UNICEF |
68 | 2004 | Survey/reported | WHO/UNICEF |
60 | 2003 | Survey/reported | WHO/UNICEF |
77 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
88 | 2019 | Survey/reported | WHO/UNICEF |
82 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Not Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Recommendations for HBV testing of pregnant women
Adopted
HBV testing policy
Risk-based
Licensed point-of-care PCR testing to detect HBV
Adopted
Eligible for HBV generic medicines
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
System for monitoring testing and treatment
Not Adopted
Recommendations for HCV testing of pregnant women
Not Adopted
HCV testing policy
Risk-based
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
Eligible for HCV generic medicines
Yes
Registration of originator HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
No
% of substance use disorder facilities offering hepatitis treatment
No
Public budget line for testing and treatment
Adopted
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.5 (0.30 - 0.60) | 2015 | Modelled | Blach et al, 2017 |
0.1 | 2015 | Survey/reported | Cabezas C, Trujillo O, Gonzales-Vivanco Á, et al. |
1.05 (0.85 - 1.31) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.84 - 1.31) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.84 - 1.30) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.84 - 1.30) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.84 - 1.29) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.84 - 1.29) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.84 - 1.30) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.85 - 1.30) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.85 - 1.31) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.84 - 1.30) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.83 - 1.29) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.01 (0.81 - 1.25) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.99 (0.79 - 1.22) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.96 (0.78 - 1.18) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.95 (0.76 - 1.16) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.94 (0.76 - 1.16) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.94 (0.75 - 1.15) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.93 (0.75 - 1.15) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.93 (0.75 - 1.14) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.93 (0.75 - 1.14) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.94 (0.75 - 1.15) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.95 (0.77 - 1.18) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.97 (0.79 - 1.21) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.99 (0.81 - 1.23) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.81 - 1.24) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.81 - 1.24) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.99 (0.80 - 1.23) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.99 (0.80 - 1.23) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.99 (0.80 - 1.22) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.98 (0.79 - 1.22) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.80 - 1.24) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.52 (0.31 - 0.56) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.2 (0.40 - 1.60) | 2014 | Survey/reported | Gower et al, 2014 |
1.16 | 2019 | Modelled | Jin et al. 2017 |
0.1 (0.02 - 0.20) | 2015 | Survey/reported | Cabezas, C., et al. 2020 |
Showing out of
Show more
Men who have sex with men (MSM) Living with HIV
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.5 (0.30 - 3.40) | 2019 | Modelled | Jin et al. 2017 |
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.5 | 2019 | Modelled | Jin et al. 2017 |
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
167,000 (99,000 - 182,000) | 2015 | Modelled | Blach et al, 2017 |
203,575 (163,058 - 253,738) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
208,488 (167,805 - 258,621) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
213,152 (171,759 - 263,013) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
217,584 (175,575 - 270,369) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
221,802 (179,012 - 275,403) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
225,821 (182,846 - 280,041) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
227,947 (184,975 - 282,096) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
227,447 (183,887 - 282,094) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
225,851 (181,942 - 278,787) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
224,878 (181,486 - 276,160) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
226,352 (182,555 - 278,792) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
229,733 (184,791 - 283,214) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
233,307 (188,738 - 287,181) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
237,113 (190,994 - 291,235) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
241,230 (194,554 - 296,067) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
245,765 (198,126 - 301,146) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
252,316 (203,781 - 309,650) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
261,492 (210,929 - 321,986) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
271,690 (218,565 - 335,505) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
281,307 (226,232 - 348,018) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
288,771 (231,597 - 357,289) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
294,347 (236,452 - 364,439) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
299,868 (241,477 - 371,713) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
306,206 (247,133 - 378,471) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
312,283 (252,374 - 385,812) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
317,973 (256,584 - 393,474) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
322,676 (261,524 - 402,893) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
328,700 (264,964 - 411,047) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
334,810 (271,288 - 420,387) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
338,348 (273,114 - 422,515) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
340,272 (274,868 - 424,634) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
44,600 (26,400 - 48,500) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
2.61 (1.66 - 3.92) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
2.48 (1.80 - 3.40) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.34 (1.69 - 3.19) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.55 (1.86 - 3.40) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.56 (1.91 - 3.47) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.49 (1.81 - 3.34) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.61 (1.94 - 3.48) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.58 (1.92 - 3.46) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.58 (1.92 - 3.50) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.48 (1.81 - 3.44) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.58 (1.89 - 3.50) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.48 (1.77 - 3.36) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.38 (1.76 - 3.29) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.36 (1.71 - 3.32) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.37 (1.73 - 3.33) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.33 (1.66 - 3.24) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.3 (1.67 - 3.19) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.32 (1.69 - 3.17) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.27 (1.63 - 3.12) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.31 (1.64 - 3.12) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.55 (1.80 - 3.51) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.62 (1.84 - 3.61) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.51 (1.80 - 3.52) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.61 (1.84 - 3.70) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.57 (1.84 - 3.56) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.43 (1.69 - 3.44) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.44 (1.75 - 3.42) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.45 (1.64 - 3.58) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.49 (1.64 - 3.62) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.61 (1.66 - 3.92) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.54 (1.65 - 3.76) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
603 | 2016 | Modelled | WHO |
887 (563 - 1,334) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
887 (563 - 1,334) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
856 (554 - 1,266) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
828 (545 - 1,202) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
800 (535 - 1,166) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
779 (543 - 1,103) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
770 (550 - 1,079) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
773 (555 - 1,083) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
771 (551 - 1,068) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
766 (540 - 1,086) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
757 (531 - 1,045) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
726 (512 - 1,000) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
650 (462 - 880) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
633 (454 - 868) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
634 (459 - 878) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
630 (461 - 861) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
626 (446 - 872) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
630 (460 - 883) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
618 (447 - 870) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
616 (455 - 851) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
634 (461 - 879) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
623 (444 - 845) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
641 (469 - 867) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
631 (468 - 854) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
620 (463 - 831) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
618 (459 - 825) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
597 (445 - 809) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
584 (427 - 779) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
560 (408 - 752) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
518 (375 - 706) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
539 (390 - 739) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Not Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Recommendations for HBV testing of pregnant women
Adopted
HBV testing policy
Risk-based
Licensed point-of-care PCR testing to detect HBV
Adopted
Eligible for HBV generic medicines
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
System for monitoring testing and treatment
Not Adopted
Recommendations for HCV testing of pregnant women
Not Adopted
HCV testing policy
Risk-based
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
Eligible for HCV generic medicines
Yes
Registration of originator HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
No
% of substance use disorder facilities offering hepatitis treatment
No
Public budget line for testing and treatment
Adopted
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Modelled
HBV
846
2019
(581 - 1,186)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
887
2019
(563 - 1,334)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.06
(%)
2020, latest modelled
(0.05 - 0.07(%))
WHO
Prevalence PWID
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Yes